Title:
MEDICINAL COMPOSITION FOR TREATING INFLAMMATORY BOWEL DISEASE
Document Type and Number:
WIPO Patent Application WO/2023/286694
Kind Code:
A1
Abstract:
There are said to be approximately five million people worldwide who suffer from inflammatory bowel diseases including ulcerative colitis and Crohn's disease, and the development of therapeutic agents is hoped for. In particular, the development of a therapeutic agent that is effective for patients who have a recognized resistance to currently existing therapeutic agents is a problem of concern. An enterocolitis amelioration effect was observed due to a neutralizing antibody that recognizes only active IL-18. Furthermore, a marked enterocolitis amelioration effect was observed due to using an anti-TNF-α antibody together therewith. A medicinal composition having an antibody that recognizes active IL-18, i.e. an antibody that recognizes a neoepitope, and a TNF-α inhibiting agent as active ingredients thereof has a marked enterocolitis amelioration effect, and thus is a therapeutic agent for inflammatory bowel disease.
More Like This:
| WO/2002/012461 | REGULATION OF HUMAN MEMBRANE-TYPE SERINE PROTEASE |
| JP6220333 | An anti-folate receptor alpha antibody and its use |
| WO/2019/213043 | ANTIBODIES WITH MODULATED GLYCAN PROFILES |
Inventors:
MAEDA KEIKO (JP)
FUJISHIRO MITSUHIRO (JP)
IKEGAMI SHUJI (JP)
URANO TAKESHI (JP)
FUJISHIRO MITSUHIRO (JP)
IKEGAMI SHUJI (JP)
URANO TAKESHI (JP)
Application Number:
PCT/JP2022/027035
Publication Date:
January 19, 2023
Filing Date:
July 07, 2022
Export Citation:
Assignee:
NATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP)
MABPROTEIN CO LTD (JP)
MABPROTEIN CO LTD (JP)
International Classes:
A61K39/395; A61K45/00; A61P1/04; A61P43/00; C07K16/24; C07K19/00; C12N15/13; C12P21/08
Domestic Patent References:
| WO2002032374A2 | 2002-04-25 | |||
| WO2020116423A1 | 2020-06-11 | |||
| WO2015032932A1 | 2015-03-12 | |||
| WO2014186728A2 | 2014-11-20 | |||
| WO2014037899A2 | 2014-03-13 | |||
| WO2001058956A2 | 2001-08-16 | |||
| WO2005047307A2 | 2005-05-26 | |||
| WO2012085015A1 | 2012-06-28 | |||
| WO2010048183A1 | 2010-04-29 | |||
| WO2007137984A2 | 2007-12-06 | |||
| WO2001062285A1 | 2001-08-30 | |||
| WO2000056771A1 | 2000-09-28 | |||
| WO2020116423A1 | 2020-06-11 | |||
| WO2004092219A2 | 2004-10-28 |
Other References:
NIELSENAINSWORTH, N ENGL J MED, vol. 369, no. 8, 2013, pages 754 - 762
GISBERT ET AL., PHARMACOL. THER., vol. 41, no. 7, 2015, pages 613 - 23
SINGH ET AL., PHARMACOL. THER., vol. 47, no. 2, 2018, pages 162 - 175
ARIMORI, T. ET AL., STRUCTURE, vol. 25, 2017, pages 1611 - 1622
HEZAREH ET AL., J. VIROL., vol. 75, 2001, pages 12161 - 12168
OGANESYAN ET AL., ACTA CRYST., vol. D64, 2008, pages 700 - 704
TAOMORRISON, J. IMMUNOL., vol. 143, 1989, pages 2595 - 2601
SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604
STEFAN WIRTZ ET AL., NATURE PROTOCOLS, vol. 12, 2017, pages 1295 - 1309
MOLGORA ET AL., NATURE, vol. 551, no. 7678, 2017, pages 110 - 114
GISBERT ET AL., PHARMACOL. THER., vol. 41, no. 7, 2015, pages 613 - 23
SINGH ET AL., PHARMACOL. THER., vol. 47, no. 2, 2018, pages 162 - 175
ARIMORI, T. ET AL., STRUCTURE, vol. 25, 2017, pages 1611 - 1622
HEZAREH ET AL., J. VIROL., vol. 75, 2001, pages 12161 - 12168
OGANESYAN ET AL., ACTA CRYST., vol. D64, 2008, pages 700 - 704
TAOMORRISON, J. IMMUNOL., vol. 143, 1989, pages 2595 - 2601
SHIELDS ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604
STEFAN WIRTZ ET AL., NATURE PROTOCOLS, vol. 12, 2017, pages 1295 - 1309
MOLGORA ET AL., NATURE, vol. 551, no. 7678, 2017, pages 110 - 114
Attorney, Agent or Firm:
SHIRAKATA Yumiko (JP)
Download PDF: